Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2021 iwNHL
27–28 January 2022 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in Non-Hodgkin Lymphoma (NHL) from ASH 2021
The Post-ASH 2021 iwNHL Virtual Workshop was held on 27-28 January 2022. The program covered key topics in the area of non-Hodgkin lymphoma. Both days featured a series of short presentations from invited experts on selected abstracts from the 63rd ASH Annual Meeting with interactive panel discussions after each session.
The Post-ASH 2021 iwNHL Workshop was supported by Janssen Oncology, Bristol Myers Squibb, Genentech, AstraZeneca and Novartis. Supporters have no influence over the production of content
Session 1: NHL; Follicular Lymphoma
Ex-vivo platform for choice of drug combinations in R/R lymphoma
Anand Jeyasekharan National University of Singapore, Singapore, Singapore
FLIPI24: EFS & OS in patients with FL treated with immunochemotherapy
Matthew Maurer Mayo Clinic, Rochester, MN, United States
Detectable tumor-confirmed FL mutations in PB years prior to clinical diagnosis
Joseph Schroers-Martin Stanford University, Stanford, CA, United States
Frontline VEN+OBI and BEN in high tumor burden FL
Craig Portell University of Virginia, Charlottesville, VA, United States
Cell-of-origin risk stratification prior to immune profiling of DLBCL biopsies
Andrew Weng BC Cancer Agency, Vancouver, Canada
MCL R2 Elderly: R2 vs RTX maintenance after immunochemotherapy in MCL
Vincent Ribrag Gustave Roussy Institute, Villejuif, France
Session 1 panel discussion
Session 2: Novel Therapies
POLARIX: pola-R-CHP vs R-CHOP in previously untreated DLBCL
Hervé Tilly Henri Becquerel Center, Rouen, France
Mosunetuzumab monotherapy in patients with R/R FL with ≥2 prior LoT
Elizabeth Budde City of Hope, Duarte, CA, United States
ACA prior to frontline therapy in untreated aggressive B-cell lymphoma
Mark Roschewski National Cancer Institute, Bethesda, MD, United States
Glofitamab + polatuzumab vedotin in R/R DLBCL
Martin Hutchings Copenhagen University Hospital, Copenhagen, Denmark
Global Unity-NHL: umbralisib plus ublituximab in R/R MZL
Julio Chavez Moffitt Cancer Center, Tampa, FL, United States
CITADEL-203: parsaclisib in R/R FL
Ryan Lynch Seattle Cancer Care Alliance, Seattle, WA, United States
Session 2 panel discussion
Session 3: CLL & SLL
DFS results from MRD cohort of Captivate
Paolo Ghia Vita-Salute San Raffaele University, Milan, Italy
GAIA (CLL13): VEN-based time-limited combination treatments vs SOC in CLL
Barbara Eichhorst University Hospital Cologne, Cologne , Germany
NCRI FLAIR: IBR+RTX vs FCR in previously untreated CLL
Talha Munir Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
MAJIC: frontline ACA+VEN vs VEN+OBI in CLL or SLL
Matthew Davids Dana-Farber Cancer Institute, Boston, MA, United States
SEQUOIA: frontline ZAN+VEN in CLL or SLL with del(17p)
Alessandra Tedeschi Niguarda Cancer Center, Milan, Italy
SEQUOIA: ZAN vs BEN+RTX in treatment-naïve CLL/SLL
Constantine Tam Peter MacCallum Cancer Centre, Victoria, Australia
Ascend: ACA vs RTX+IDL or BEN in R/R CLL
Wojciech Jurczak Jagiellonian University, Krakow, Poland
Glow: MRD outcomes after fixed-duration IBR+VEN vs CLB+OBI in CLL
Talha Munir Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Session 3 panel discussion
Session 4: T-Cell Engagement & Therapies
Transform: liso-cel vs SOC + salvage chemotherapy and ASCT in R/R LBCL
Manali Kamdar University of Colorado Cancer Center, Denver, CO, United States
ZUMA-5: axi-cel in patients with R/R iNHL
Sattva Neelapu The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Elara: tisa-cel in adult patients with high-risk R/R FL
Catherine Thieblemont Saint-Louis Hospital, Paris, France
First-in-human study of YTB323 CAR-T therapy in patients with R/R DLBCL
Ian Flinn Sarah Cannon Research Institute, Nashville, TN, United States
High durable remission rates after CD22-CAR-T therapy in adults with R/R LBCL
Matthew Frank Stanford University, Stanford, CA, United States
Real-world data from US Lymphoma CAR T Consortium: brexu-cel for R/R MCL
Yucai Wang Mayo Clinic, Rochester, MN, United States
CD30-directed CAR-Ts co-expressing CCR4 in R/R HL and CD30+ CTCL
Natalie Grover UNC School of Medicine, Chapel Hill, NC, United States
Session 4 panel discussion
Meeting Supporters:
Visit The Lymphoma channel for the latest updates from leading experts
